CRA analyzed the lost profits and reasonable royalty damages sustained by a manufacturer assuming its patents to be valid and infringed as they relate to a rare immunology condition. The damages assessment considered the impact of infringement on the manufacturer’s marketed therapy as well as its pipeline agent, and determined the reasonable royalty rate from a hypothetical negotiation based on similar licensing agreements. Dr. Gregory K. Bell provided expert opening and reply reports to support the damages assessment. CRA further supported counsel by assessing the damages theories put forth by the opposing expert. Ultimately, this case settled prior to trial.
Patent damages: Recent trends in Rule 702 decisions
Rule 702 decision trends are based on our review of available US district court decisions concerning damages experts in patent infringement matters that have...